SEARCH

SEARCH BY CITATION

References

  • Arispe N., Rojas E. and Pollard H. B. (1993) Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl Acad. Sci. USA 90, 567571.
  • Choo Y. S., Johnson G. V., MacDonald M., Detloff P. J. and Lesort M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 14071420.
  • Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T. Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571576.
  • Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. Jr (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine–α-synuclein adduct. Science 294, 13461349.
  • Da Costa C. A., Ancolio K. and Checler F. (2000) Wild-type but not Parkinson's disease-related ala-53 [RIGHTWARDS ARROW] Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24 06524 069.
  • Furukawa K., Abe Y. and Akaike N. (1994) Amyloid β protein-induced irreversible current in rat cortical neurones. Neuroreport 5, 20162018.
  • Furukawa K., Smith-Swintosky V. L. and Mattson M. P. (1995) Evidence that actin depolymerization protects hippocampal neurons against excitotoxicity by stabilizing [Ca2+]i. Exp. Neurol. 133, 153163.
  • Furukawa K., Wang Y., Yao P. J. et al. (2003) Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J. Neurochem. 87, 427436.
  • Hamill O. P., Marty A., Neher E., Sakmann B. and Sigworth F. J. (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 391, 85100.
  • Hasegawa T., Matsuzaki M., Takeda A., Kikuchi A., Akita H., Perry G., Smith M. A. and Itoyama Y. (2004) Accelerated α-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res. 1013, 5159.
  • Hashimoto M. and Masliah E. (1999) α-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 9, 707720.
  • Kayed R., Sokolov Y., Edmonds B., McIntire T. M., Milton S. C., Hall J. E. and Glabe C. G. (2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279, 46 36346 366.
  • Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J. and Bjorklund A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 27802791.
  • Kourie J. I. and Culverson A. (2000) Prion peptide fragment PrP[106−126] forms distinct cation channel types. J. Neurosci. Res. 62, 120133.
  • Kruger R., Kuhn W., Muller T. et al. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106108.
  • Lashuel H. A., Hartley D., Petre B. M., Walz T. and Lansbury P. T. Jr (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
  • Lee H. J. and Lee S. J. (2002) Characterization of cytoplasmic α-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48 97648 983.
  • Lee H. G., Petersen R. B., Zhu X., Honda K., Aliev G., Smith M. A. and Perry G. (2003) Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases? Brain Pathol. 13, 630638.
  • Lee M., Hyun D., Halliwell B. and Jenner P. (2001) Effect of the overexpression of wild-type or mutant α-synuclein on cell susceptibility to insult. J. Neurochem. 76, 9981009.
  • Lucero M. T. and Pappone P. A. (1990) Membrane responses to norepinephrine in cultured brown fat cells. J. Gen. Physiol. 95, 523544.
  • Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 12651269.
  • Matsuzaki M., Hasegawa T., Takeda A., Kikuchi A., Furukawa K., Kato Y. and Itoyama Y. (2004) Histochemical features of stress-induced aggregates in α-synuclein overexpressing cells. Brain Res. 1004, 8390.
  • Mattson M. P. and Chan S. L. (2001) Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J. Mol. Neurosci. 17, 205224.
  • Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 20452047.
  • Saha A. R., Ninkina N. N., Hanger D. P., Anderton B. H., Davies A. M. and Buchman V. L. (2000) Induction of neuronal death by α-synuclein. Eur. J. Neurosci. 12, 30733077.
  • Singleton A. B., Farrer M., Johnson J. et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
  • Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) α-synuclein in Lewy bodies. Nature 388, 839840.
  • Volles M. J. and Lansbury P. T. Jr (2002) Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 45954602.
  • Wakamori M., Hidaka H. and Akaike N. (1993) Hyperpolarizing muscarinic responses of freshly dissociated rat hippocampal CA1 neurones. J. Physiol. 463, 585604.